Literature DB >> 9143346

Exendin-4 agonist and exendin(9-39)amide antagonist of the GLP-1(7-36)amide effects in liver and muscle.

A I Alcántara1, M Morales, E Delgado, M I López-Delgado, F Clemente, M A Luque, W J Malaisse, I Valverde, M L Villanueva-Peñacarrillo.   

Abstract

The GLP-1 structurally related peptides exendin-4 and exendin(9-39)amide were found to act, in rat liver and skeletal muscle, as agonist and antagonist, respectively, of the GLP-1(7-36)amide effects on glucose metabolism. Thus, like GLP-1(7-36)amide, exendin-4 increased glycogen synthase a activity and glucose incorporation into glycogen in both tissues and also stimulated exogenous D-glucose utilization and oxidation in muscle. These effects of GLP-1(7-36)amide and exendin-4 were inhibited by exendin(9-39)amide. Our findings provide further support to the proposed use of GLP-1, or exendin-4, as a tool in the treatment of diabetes mellitus. Thus, in addition to the well-known insulinotropic action of the peptides, they act both in liver and in muscle in a manner most suitable for restoration of glucose homeostasis, with emphasis on their positive effects upon glycogen synthesis in the two tissues and on the stimulation of exogenous glucose catabolism in muscle.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9143346     DOI: 10.1006/abbi.1997.9951

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  15 in total

Review 1.  Diabetes pharmacotherapy and effects on the musculoskeletal system.

Authors:  Evangelia Kalaitzoglou; John L Fowlkes; Iuliana Popescu; Kathryn M Thrailkill
Journal:  Diabetes Metab Res Rev       Date:  2018-12-20       Impact factor: 4.876

2.  Insulin secretion-independent effects of GLP-1 on canine liver glucose metabolism do not involve portal vein GLP-1 receptors.

Authors:  Dominique Dardevet; Mary Courtney Moore; Catherine A DiCostanzo; Ben Farmer; Doss W Neal; Wanda Snead; Margaret Lautz; Alan D Cherrington
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2005-07-28       Impact factor: 4.052

3.  Suppression by exendin(9-39)amide of glucagon-like peptide-1 insulinotropic action in rats infused with dimethyl ester of succinic acid.

Authors:  J Cancelas; M L Villanueva-Peñacarrillo; I Valverde; W J Malaisse
Journal:  Endocrine       Date:  2001-08       Impact factor: 3.633

Review 4.  The role of incretins in glucose homeostasis and diabetes treatment.

Authors:  Wook Kim; Josephine M Egan
Journal:  Pharmacol Rev       Date:  2008-12-12       Impact factor: 25.468

5.  Effects of intraportal exenatide on hepatic glucose metabolism in the conscious dog.

Authors:  Dale S Edgerton; Zhibo An; Kathryn M S Johnson; Tiffany Farmer; Ben Farmer; Doss Neal; Alan D Cherrington
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-05-14       Impact factor: 4.310

Review 6.  CNS GLP-1 regulation of peripheral glucose homeostasis.

Authors:  Darleen Sandoval
Journal:  Physiol Behav       Date:  2008-05-27

7.  Exenatide sensitizes insulin-mediated whole-body glucose disposal and promotes uptake of exogenous glucose by the liver.

Authors:  Dan Zheng; Viorica Ionut; Vahe Mooradian; Darko Stefanovski; Richard N Bergman
Journal:  Diabetes       Date:  2008-11-14       Impact factor: 9.461

Review 8.  Clinical review: The extrapancreatic effects of glucagon-like peptide-1 and related peptides.

Authors:  Rania Abu-Hamdah; Atoosa Rabiee; Graydon S Meneilly; Richard P Shannon; Dana K Andersen; Dariush Elahi
Journal:  J Clin Endocrinol Metab       Date:  2009-03-31       Impact factor: 5.958

Review 9.  Oxidative Stress, Intrauterine Growth Restriction, and Developmental Programming of Type 2 Diabetes.

Authors:  Cetewayo S Rashid; Amita Bansal; Rebecca A Simmons
Journal:  Physiology (Bethesda)       Date:  2018-09-01

10.  Glucagon like peptide-1-induced glucose metabolism in differentiated human muscle satellite cells is attenuated by hyperglycemia.

Authors:  Charlotte J Green; Tora I Henriksen; Bente K Pedersen; Thomas P J Solomon
Journal:  PLoS One       Date:  2012-08-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.